144 related articles for article (PubMed ID: 38240169)
21. Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
Kido K; Hatakeyama S; Numakura K; Tanaka T; Oikawa M; Noro D; Hosogoe S; Narita S; Inoue T; Yoneyama T; Ito H; Nishimura S; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C
Int J Clin Oncol; 2021 Jan; 26(1):154-162. PubMed ID: 33067647
[TBL] [Abstract][Full Text] [Related]
22. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.
Yang Y; Psutka SP; Parikh AB; Li M; Collier K; Miah A; Mori SV; Hinkley M; Tykodi SS; Hall E; Thompson JA; Yin M
Cancer Med; 2022 Aug; 11(16):3106-3114. PubMed ID: 35304832
[TBL] [Abstract][Full Text] [Related]
23. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
[TBL] [Abstract][Full Text] [Related]
25. Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma.
Cao X; Tang D; Ratto B; Poole A; Ravichandran S; Jin L; Gao W; Swallow E; Vogelzang NJ
Clin Genitourin Cancer; 2020 Feb; 18(1):e37-e45. PubMed ID: 31727510
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
27. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
28. Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis.
Bolek H; Yekedüz E; Ürün Y
Cancer Treat Rev; 2024 Jan; 122():102667. PubMed ID: 38101099
[TBL] [Abstract][Full Text] [Related]
29. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
Zarrabi KK; Handorf E; Miron B; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
Oncologist; 2023 Feb; 28(2):157-164. PubMed ID: 36200791
[TBL] [Abstract][Full Text] [Related]
30. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
31. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
33. The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Scand J Immunol; 2023 Oct; 98(4):e13304. PubMed ID: 37294700
[TBL] [Abstract][Full Text] [Related]
34. Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Chen YW; Rini BI
Curr Oncol Rep; 2022 Jun; 24(6):695-702. PubMed ID: 35247142
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Tyrosine Kinase Inhibitor
Miyake H; Imai S; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Anticancer Res; 2017 Mar; 37(3):1523-1528. PubMed ID: 28314328
[TBL] [Abstract][Full Text] [Related]
36. Real world treatment sequences and outcomes for metastatic renal cell carcinoma.
Lai GS; Li JR; Wang SS; Chen CS; Yang CK; Lin CY; Hung SC; Chiu KY; Yang SF
PLoS One; 2023; 18(11):e0294039. PubMed ID: 37992086
[TBL] [Abstract][Full Text] [Related]
37. Efficacy analyses of axitinib and nivolumab in metastatic renal cell carcinoma after failure of targeted therapy: which is better?
Halit Aktepe O; Sinem Ardic F; Yuce D; Can Guven D; Guner G; Cagri Yildirim H; Kilickap S; Turker A; Kertmen N; Akin S; Aksoy S; Dizdar O; Yalcin S; Erman M
J BUON; 2021; 26(5):2067-2073. PubMed ID: 34761618
[TBL] [Abstract][Full Text] [Related]
38. IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time.
Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Panunzio A; Tappero S; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Antonelli A; Kosiba M; Kluth LA; Becker A; Chun FKH; Karakiewicz PI
Semin Oncol; 2022 Oct; 49(5):394-399. PubMed ID: 36333148
[TBL] [Abstract][Full Text] [Related]
39. First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology.
Numakura K; Kobayashi M; Muto Y; Sekine Y; Takahashi M; Kashima S; Yamamoto R; Koizumi A; Nara T; Saito M; Narita S; Nanjyo H; Habuchi T
Sci Rep; 2020 Nov; 10(1):20089. PubMed ID: 33208816
[TBL] [Abstract][Full Text] [Related]
40. [Risk-adapted therapy for metastatic renal cell carcinoma].
Grimm MO; Leucht K; Foller S; Grünwald V
Urologe A; 2020 Feb; 59(2):155-161. PubMed ID: 32006060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
